Molecule
Dexlansoprazole is a proton pump inhibitor indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE), among other approved uses. It is available as delayed-release capsules for oral use. MedsAcross supplies Dexlansoprazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
DEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). Maintenance of healed EE and relief of heartburn. Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD).
Source: US FDA prescribing information
Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H +, K + )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
Source: US FDA prescribing information
Recommended dosage in patients 12 years of age and older: See full prescribing information for complete dosing information for DEXILANT by indication and age group and dosage adjustment in patients with hepatic impairment. Administration Instructions: Take without regard to food. Swallow whole, do not chew. See full prescribing information for alternative administration options.
Source: US FDA prescribing information
DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis and urticaria. PPIs, including DEXILANT, are contraindicated with rilpivirine-containing products. Patients with known hypersensitivity to any component of the formulation. Patients receiving rilpivirine-containing products.
Source: US FDA prescribing information
Gastric Malignancy: In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing. Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients. Clostridium difficile -Associated Diarrhea: PPI therapy may be associated with increased risk. Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous, new onset or exacerbation of existing disease, discontinue DEXILANT and refer to specialist for evaluation.
Source: US FDA prescribing information
The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis Clostridium difficile -Associated Diarrhea Bone Fracture Severe Cutaneous Adverse Reactions Cutaneous and Systemic Lupus Erythematosus Cyanocobalamin (Vitamin B12) Deficiency Hypomagnesemia and Mineral Metabolism Fundic Gland Polyps Risk of Heart Valve Thickening in Pediatric Patients Less than Two Years of Age The most common adverse reactions are: Adults (≥2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence. Patients 12 to 17 years of age (≥5%): headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
Source: US FDA prescribing information
Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with DEXILANT and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3. Clinically Relevant Interactions Affecting Drugs Coadministered with DEXILANT and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance.
Source: US FDA prescribing information
Store at 20 to 25°C (68 to 77°F), excursions permitted to 15 to 30°C (59 to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Dexlansoprazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dexlansoprazole 60 mg delayed-release capsuleOralGeneric name | — | US FDA | Available on request |
| Dexlansoprazole 30 mg delayed-release capsuleOralGeneric name | — | US FDA | Available on request |
| Dexilant 30 mg delayed-release capsuleOral | Takeda Pharmaceuticals | US FDA | Available on request |
| Dexilant 60 mg delayed-release capsuleOral | Takeda Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 January 2009 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dexlansoprazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Dexlansoprazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dexlansoprazole, including Dexilant.
Yes. The US FDA first approved Dexlansoprazole on 30 January 2009, according to Drugs@FDA.
No listed presentation of Dexlansoprazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dexlansoprazole is classified under ATC code A02BC06 (Dexlansoprazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.